Aditxt announced it has acquired Ignite Proteomics, a commercial-stage precision oncology company focused on improving cancer therapy selection. The transaction was structured through the issuance of 36,000 shares of Aditxt’s newly designated Series A-2 convertible preferred stock, representing an aggregate stated value of $36 million. Following the acquisition, Ignite will operate as a subsidiary within Aditxt’s oncology initiatives.
Ignite’s technology is designed to address a key challenge in cancer treatment: determining which therapies are most likely to work for individual patients. The company’s functional proteomics platform analyzes protein expression and activity within tumors, offering insights that may not be captured by standard genomic testing alone.
The platform uses Reverse Phase Protein Array (RPPA) technology to measure phospho- and total-protein biomarkers directly from tumor biopsy samples. This approach focuses on the biological activity of proteins within cancer cells, which can play a critical role in determining whether targeted therapies will be effective.
According to the company, Ignite’s system could help support therapy selection and longitudinal monitoring as precision medicine continues expanding. Ignite plans to deploy its platform through a phased rollout integrating the technology into oncology practices and Molecular Tumor Boards, initially focusing on patients where conventional biomarker guidance is limited.
Ignite operates a CLIA-certified laboratory and has an established Medicare Proprietary Laboratory Analyses reimbursement pathway valued at approximately $2,200 per test. This commercial infrastructure positions the company to support clinical adoption as targeted cancer therapies and antibody drug conjugates become more widely used.
The company estimates that more than 600,000 patients in the United States living with metastatic cancer and limited treatment options could benefit from improved therapy selection tools. Market research cited in the announcement estimates the global cancer profiling market at roughly $14 billion, with approximately $3 billion in serviceable opportunity tied to patients eligible for antibody drug conjugate therapies and other targeted treatments.
Ignite’s platform is also being evaluated through collaborations with leading cancer research institutions including Dana-Farber Cancer Institute at Harvard, Vanderbilt University Medical Center, and other National Cancer Institute-designated centers. The company has also entered into a collaboration with Inova Health to analyze up to 600 tumor samples from patients with late-stage gastrointestinal cancers.
Through the acquisition, Aditxt said Ignite’s technology will complement its broader strategy of advancing healthcare innovation through its discovery, development, and deployment model.
KEY QUOTES
“Each year nearly 20 million people are diagnosed with cancer worldwide, tens of millions undergo treatment, and millions of patients with advanced disease ultimately face limited therapeutic options. These realities underscore the importance of improving how therapies are selected, particularly as precision medicines increasingly depend on identifying whether a patient’s tumor expresses the intended biological targets for those therapies. We believe there is a real need for tools that can provide physicians with additional information to help support more informed treatment decisions, particularly as targeted therapies become more precise and more complex. This acquisition reflects the continued execution of our Discovery, Development, and Deployment model, which is focused on identifying and advancing companies addressing important challenges in healthcare. We believe Ignite adds a differentiated platform to our oncology efforts at a time when treatment selection and longitudinal monitoring are becoming increasingly important in cancer care.”
Amro Albanna — Co-Founder And Chief Executive Officer, Aditxt
“For many cancers, the key clinical question is not only what mutations are present, but whether the relevant signaling pathways are actually active in the tumor. That is where functional proteomics can add value. Ignite’s RPPA platform is designed to measure phospho- and total-protein biomarkers directly from biopsy material, which may provide information that complements genomic testing and helps support clinical decision-making, particularly in settings where conventional biomarker guidance is limited.”
Shahrokh Shabahang — Co-Founder And Chief Innovation Officer, Aditxt
